Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Increase in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 49,200 shares, a growth of 693.5% from the February 28th total of 6,200 shares. Based on an average trading volume of 1,280,500 shares, the short-interest ratio is presently 0.0 days. Currently, 0.2% of the company’s stock are sold short.

Bioxytran Stock Down 4.5 %

BIXT traded down $0.01 during trading on Friday, hitting $0.15. The company had a trading volume of 102,826 shares, compared to its average volume of 292,547. The company has a market capitalization of $13.04 million, a PE ratio of -14.80 and a beta of 2.00. Bioxytran has a one year low of $0.06 and a one year high of $0.21. The firm’s 50-day moving average price is $0.11 and its 200 day moving average price is $0.10.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.